"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04390139","Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19","COVIDMES","Active, not recruiting","No Results Available","COVID-19|SARS-CoV 2|Adult Respiratory Distress Syndrome","Drug: XCEL-UMC-BETA|Other: Placebo","All-cause mortality at day 28|Safety of WJ-MSC|Need for treatment with rescue medication|Need and duration of mechanical ventilation|Ventilator free days|Evolution of PaO2 / FiO2 ratio|Evolution of the SOFA index|Evolution of the APACHE II score|Duration of hospitalization|Evolution of markers of immune response (leucocyte count, neutrophils)|Feasibility of WJ-MSC administration|Evolution of disease biomarker: polymerase chain reaction (RT-PCR)|Evolution of disease biomarker: lactate dehydrogenase (LDH)|Evolution of disease biomarker: D-dimer|Evolution of disease biomarker: Ferritin","Banc de Sang i Teixits","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BST-COVID-01","May 13, 2020","September 2022","December 2022","May 15, 2020",,"July 6, 2022","Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Mútua de Terrassa, Terrassa, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04390139"
2,"NCT05054803","Cell Therapy for Chronic Traumatic Cervical Incomplete Spinal Cord Injury",,"Active, not recruiting","No Results Available","Spinal Cord Injury Cervical","Drug: WJ-MSC (XCEL-UMC-BETA)|Drug: Placebo","Incidence of adverse events|American Spinal Injury Association (ASIA) impairment scale|Motor evoked potentials|Somatosensory evoked potentials|Electrical pain threshold perception|Handgrip Strength|Walking index for spinal cord injury (WISCI II)|Numerical scale for neuropathic pain assessment|Modified Ashworth scale for spasticity|Spinal Cord Independence Measure III (SCIM III)|World Health Organization Quality of life questionnaire (WHOQOL-BREF)|Psychological general well-being index (PGWBI)|Hospital Anxiety and Depression Scale (HADS)|Community Integration Questionaire (CIQ-IG)|AntiHLA antibodies in cerebrospinal fluid (CSF)|Detection of donor cells in CSF","Banc de Sang i Teixits|Institut Guttmann|Academic Research Organization (ARO) - VHIR|Complexo Hospitalario Universitario de A Coruña","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BST-SCI-02","October 13, 2021","October 2023","October 2025","September 23, 2021",,"July 8, 2022","Hospital de Neurorehabilitació Institut Guttmann, Badalona, Barcelona, Spain|Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain",,"https://ClinicalTrials.gov/show/NCT05054803"
